Press Release: GlycoMimetics to Report Fourth Quarter and Year-End 2020 Financial Results on March 2
Press Release: GlycoMimetics to Report Fourth Quarter and Year-End 2020 Financial Results on March 2
Press Release: GlycoMimetics to Report Fourth Quarter and Year-End 2020 Financial Results on March 2
新闻稿:GlycoMimtics将于3月2日公布2020年第四季度和年终财务业绩
GlycoMimetics to Report Fourth Quarter and Year-End 2020 Financial Results on March 2
GlycoMimtics将于3月2日公布2020年第四季度和年终财务业绩
ROCKVILLE, Md.--(BUSINESS WIRE)--February 23, 2021--
马里兰州罗克维尔--(美国商业新闻网)--2021年2月23日--
GlycoMimetics, Inc. (Nasdaq: GLYC), today announces that it will host a conference call and webcast to report fourth quarter and year-end 2020 financial results on Tuesday, March 2, 2021, at 8:30 a.m. ET.
亚洲网加利福尼亚州圣克拉拉3月2日电GlycoMimtics,Inc.(纳斯达克市场代码:GYC)今天宣布,该公司将于2021年3月2日(星期二)上午8:30主持电话会议和网络直播,公布2020年第四季度和年终财务业绩。Et.
The dial-in number for the conference call is (844) 413-7154 for domestic participants or (216) 562-0466 for international participants, with participant code 1034166. Participants are encouraged to connect 15 minutes in advance of the call to ensure that all callers are able to connect.
国内参会者的拨入号码为(844)4137154,国际参会者的拨入号码为(216)562-0466,参会者代码为1034166。鼓励参与者在通话前15分钟接通,以确保所有呼叫者都能接通。
A webcast replay will be available via the "Investors" tab on the GlycoMimetics website for 30 days following the call. A dial-in phone replay will be available for 24 hours after the close of the call by dialing (855) 859-2056 for domestic participants and (404) 537-3406 for international participants, participant code 1034166.
电话会议结束后30天内,可通过GlycoMimtics网站上的“投资者”标签收看网络直播重播。在会议结束后的24小时内,国内参会者可拨打(855)8592056,国际参会者可拨打(4045373406),参会者代码为1034166。
About GlycoMimetics, Inc.
关于GlycoMimtics公司
GlycoMimetics is a biotechnology company with a focus in hematology-oncology and a pipeline of novel glycomimetic drugs, all designed to address unmet medical needs resulting from diseases in which carbohydrate biology plays a key role. GlycoMimetics' drug candidate, uproleselan, an E-selectin antagonist, was evaluated in a Phase 1/2 clinical trial as a potential treatment for AML and is being evaluated across a range of patient populations including in a Company-sponsored Phase 3 trial in relapsed/refractory AML under Breakthrough Therapy Designation. Rivipansel, a pan-selectin antagonist, is being explored for use in treatment of acute VOC in sickle cell disease. GlycoMimetics has also completed a Phase 1 clinical trial with another wholly-owned drug candidate, GMI-1359, a combined CXCR4 and E-selectin antagonist. GlycoMimetics is located in Rockville, MD in the BioHealth Capital Region. Learn more at www.glycomimetics.com.
GlycoMimtics是一家生物技术公司,专注于血液肿瘤学和一系列新型仿糖药物的流水线,所有这些药物都是为了解决因碳水化合物生物学起关键作用的疾病而导致的未得到满足的医疗需求。GlycoMimtics的候选药物uproleselan是一种E-选择素拮抗剂,在1/2期临床试验中作为治疗急性髓细胞白血病的潜在方法进行了评估,目前正在一系列患者中进行评估,其中包括公司赞助的突破性治疗指定的复发/难治性急性髓细胞白血病的3期试验。Rivipansel是一种泛选择素拮抗剂,正在探索用于治疗镰状细胞疾病的急性VOC。GlycoMimtics还完成了与另一种全资候选药物GMI-1359的一期临床试验,GMI-1359是一种CXCR4和E-选择素联合拮抗剂。GlycoMimtics公司位于马里兰州罗克维尔,位于生物健康首都地区。欲了解更多信息,请访问www.garcomimetics.com。
View source version on businesswire.com: https://www.businesswire.com/news/home/20210223006084/en/
在business wire.com上查看源代码版本:https://www.businesswire.com/news/home/20210223006084/en/
CONTACT: Investors:
联系人:投资者:
Shari Annes
莎莉·安尼斯(Shari Annes)
Phone: 650-888-0902
电话:650-888-0902
Email: sannes@annesassociates.com
电子邮件:sannes@annesAssociates.com
Media:
媒体:
Jamie Lacey-Moreira
杰米·莱西-莫雷拉
Phone: 410-299-3310
电话:410-299-3310
Email: jamielacey@presscommpr.com
电子邮件:jamielacey@presscommpr.com
(END) Dow Jones Newswires
(完)道琼通讯社
February 23, 2021 16:41 ET (21:41 GMT)
2021年2月23日美国东部时间16:41(格林尼治标准时间21:41)
译文内容由第三方软件翻译。